Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Janjigian, Y. Y., Al-Batran, S-E., Wainberg, Z. A., Van Cutsem, E., Molena, D., Muro, K., Hyung, W. J., Wyrwicz, L. S., Oh, D. Y., Omori, T., Moehler, M., Garrido, M., Oliveira, S. Cunha Sousa, Liberman, M., Oliden, V. Castro, Bilici, M., Kurland, J. F., Xynos, I., Mann, H., Tabernero, J.